|

Mitomycin-C Clinical Trials

6 actively recruiting trials across 3 locations

Also known as: HIPEC, Sequential treatment group

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 2Phase 4: 1

Top Sponsors

  • University of Southampton1
  • National Cancer Institute (NCI)1
  • National Cancer Center, Korea1
  • Janssen Research & Development, LLC1
  • Jakob Kristian Jakobsen1

Indications

  • Cancer6
  • Atypical Mesothelial Proliferation1
  • Non-Muscle Invasive Bladder Neoplasms1
  • Peritoneal Mesothelioma1
  • Anal Squamous Cell Carcinoma1

Other3 trials

Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer
Phase 4
Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)
Phase 3
The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy
Phase 2

Lakewood, Colorado1 trial

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Colorado Clinical Research

Phase 3

Bethesda, Maryland1 trial

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

National Institutes of Health Clinical Center

Phase 1

New York, New York1 trial

Adaptive Radiation in Anal Cancer

Columbia University Irving Medical Center

N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.